This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Immunomedics Announces Outcome Of 2013 Annual Meeting Of Stockholders

"Another new and exciting development is with our antibody-drug conjugates (ADCs) for solid cancer therapy. Both IMMU-132 (TROP-2-SN-38) and IMMU-130 (labetuzumab-SN-38) have produced partial responses and stable disease in patients who have failed multiple prior therapies, including irinotecan, the parent drug of SN-38. While IMMU-130 is focused on colorectal cancer, IMMU-132 has produced partial responses in very advanced colorectal, triple negative breast and small cell lung cancer patients. Both programs have entered into Phase II clinical development," Ms. Sullivan added.

"In all, more than 80%, or 20 of the 24 assessable patients, showed evidence of disease control with stable disease or partial responses achieved with IMMU-132 in the Phase I trial just completed. Impressively, this includes 8 patients who had failed prior irinotecan-containing therapies. Because irinotecan is the parent of SN-38, we postulate that the increased amount of SN-38 delivered to the tumors by our ADCs overcomes the tumor's resistance to this class of drugs," commented Dr. William A. Wegener, Senior Vice President of Clinical Research, in his summary of the year's clinical developments focusing on the Company's two most exciting programs, one in pancreatic cancer and the other in solid cancers with our antibody-SN-38 conjugates.

"In terms of time-to-progression for the IMMU-132 program, of the 20 patients who reported a partial response or stable disease as their best response, the duration ranges were from 4.5 weeks to more than 35 weeks, with 7 patients continuing with their treatments. The ability to achieve some measure of disease control with this ADC by itself is impressive, since this is a group of heavily pretreated patients with few other therapeutic options. To date, there have been no anti-antibody or anti-SN38 immune responses in patients treated with IMMU-132, even with long-term therapy. Major side effects are neutropenia and diarrhea, with minor side effects being fatigue and alopecia," concluded Dr. Wegener.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs